drugset / Trial / NCT00781443

A Study to Evaluate MILR1444A in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma

NCT00781443

Phase 2 Completed 29 enrolled Genentech, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a multicenter, randomized, double-blind, placebo-controlled study designed to demonstrate the safety and efficacy of MILR1444A compared with placebo in reducing the airway reaction to an inhaled aeroallergen solution in adult patients with mild allergic asthma. The study will randomize approximately 24 patients at five study centers. In the event of patient discontinuation from the study, additional patients may be enrolled at the discretion of the Sponsor.

Timeline

Start
2008-12
Primary completion
2009-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Lebrikizumab Monoclonal antibody 5 mg/kg Subcutaneous

Indications